Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic lymphocytic leukemia (CLL) Posts on Medivizor

Searching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.

Searching for patients with unresponsive chronic lymphocytic leukemia to trial an experimental treatment.

Posted by on Aug 15, 2021 in Leukemia | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including chronic lymphocytic leukemia (CLL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....

Read More

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years....

Read More

Acalabrutinib treatment for ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Acalabrutinib treatment for ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on May 8, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was suitable for patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib (Imbruvica).   This study concluded that acalabrutinib was effective and well tolerated in these patients.   Some...

Read More

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Evaluating the outcomes of venetoclax treatment in patients with chronic lymphocytic leukemia in the real-world setting

Posted by on Mar 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate whether venetoclax (Venclexta) is effective and well tolerated in patients with chronic lymphocytic leukemia (CLL) in a real-world setting.  This study concluded that venetoclax is safe and effective in the real-world setting in these patients.   Some background...

Read More

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...

Read More

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Looking for patients with untreated chronic lymphocytic leukemia to trial a treatment combination.

Posted by on Oct 11, 2020 in Leukemia | 0 comments

In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...

Read More

Blood Cancer Awareness Month: CLL

Blood Cancer Awareness Month: CLL

Posted by on Sep 27, 2020 in Blog, Leukemia | 2 comments

CLL or Chronic Lymphocytic Leukemia results from a mutation in B lymphocytes, a type of white blood cell that develops in the bone marrow. B-cells produce antibodies, an important part of the immune system. CLL can be slow growing, with small slow changes in the blood counts over years or fast growing, where cancerous B-lymphocytes crowd out the bone...

Read More

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Jul 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...

Read More